GlassScriptPhysician profile
Sheila M Amar
NPI 1003962689
$6,466.81
in general payments reported to CMS, 2019-2025
30 companies · $1,173 in 2025
The $1,173 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $839 · 2020: $837 · 2021: $988 · 2022: $1,127 · 2023: $811 · 2024: $691 · 2025: $1,173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,540 · Education: $134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,540.39 |
| Education | $134.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,956.52 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,853.57 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $597.59 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $492.13 | 2019-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $307.95 | 2019-2023 | |
| Kaleo, INC. | $291.01 | 2019-2023 | Auvi-Q |
| Amgen INC. | $153.93 | 2022-2025 | Tezspire |
| Novartis Pharmaceuticals Corporation | $126.26 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $80.38 | 2020-2021 | |
| Optinose US, INC. | $73.10 | 2019-2025 | |
| Csl Behring | $58.11 | 2020-2025 | Hizentra, Andembry |
| Genentech USA, INC. | $52.35 | 2020-2022 | |
| Alk-Abello, INC | $51.52 | 2019-2023 | Ragwitek, Odactra, Grastek |
| Hikma Pharmaceuticals USA | $44.36 | 2022-2023 | Ryaltris |
| Takeda Pharmaceuticals U.S.A., INC. | $42.37 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $37.57 | 2019-2020 | |
| Leo Pharma INC. | $24.07 | 2022 | |
| Abbvie INC. | $21.40 | 2022 | |
| Grifols USA, LLC | $21.12 | 2024 | Prolastin-C Liquid |
| Paratek Pharmaceuticals, INC. | $20.48 | 2025 | Xhance |
| Biocryst Pharmaceuticals, INC. | $20.29 | 2020 | |
| Azurity Pharmaceuticals, INC. | $19.39 | 2025 | Alvesco |
| Mylan Specialty L.P. | $19.24 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $18.11 | 2025 | Neffy |
| Hospira, INC. | $17.54 | 2024 | |
| Philips North America LLC | $15.71 | 2021 | |
| Octapharma USA, INC. | $14.93 | 2023 | Cutaquig |
| Greer Laboratories, INC. | $13.46 | 2019 | |
| Merck Sharp & Dohme LLC | $11.29 | 2021 | |
| Biocryst US Sales Co., LLC | $11.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sheila Amar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.